Preclinical Evaluation

These assessments examine complementary aspects of a candidate medicine. Pharmacology addresses biological activity, pharmacokinetics examines how the candidate behaves in the body, and pharmacodynamics evaluates its effects on biological systems. Together with dose-response findings, they show how activity changes with exposure and dose, helping researchers identify conditions that may support further development and clinical study design.

In vitro experiments allow researchers to examine biological activity and interactions under controlled conditions, while relevant animal models provide information from a more integrated biological system. Using both approaches gives a broader assessment than either alone. Their combined findings help researchers compare experimental responses, identify potential concerns, and judge whether evidence is sufficient to support progression toward human testing.

Toxicity studies help identify adverse effects associated with a potential medicine and clarify the conditions under which those effects occur. Researchers consider these findings alongside biological activity, pharmacokinetics, pharmacodynamics, and dose-response results. This integrated evidence can reveal important safety concerns, support refinement of dosing conditions, or indicate that a candidate is not suitable for clinical development.

Outcomes depend on the candidate’s biological activity, dose-response behavior, pharmacokinetic properties, pharmacodynamic effects, and toxicity findings. The choice of in vitro systems and relevant animal models also influences the evidence generated. Because these elements address different aspects of performance and safety, researchers interpret them together rather than relying on a single experiment or endpoint.

A typical assessment combines in vitro experiments with studies in relevant animal models, followed by integrated analysis of pharmacology, pharmacokinetics, pharmacodynamics, dose response, and toxicity. Researchers use the resulting evidence to examine biological effects, adverse findings, and dosing conditions. The conclusions then inform whether and how a candidate should advance to clinical trials.

The findings help establish dosing conditions and identify biological effects that may be important when planning human studies. Pharmacokinetic and pharmacodynamic results describe candidate behavior and effects, while dose-response and toxicity data contribute safety context. This evidence supports informed decisions about experimental strategy and helps refine how a potential medicine is evaluated in clinical development.

The approach can be applied to drugs, biologics, and other medical interventions. Although the specific experimental strategy may differ between candidates, the assessment focuses on evidence about biological activity, safety, pharmacokinetics, pharmacodynamics, dose response, and toxicity. This broad applicability makes the process useful for deciding whether different kinds of potential therapies are ready for human investigation.